Achieve Life Sciences, Inc. (NASDAQ:ACHV) CFO Purchases $28,900.00 in Stock

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) CFO Mark K. Oki bought 10,000 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average price of $2.89 per share, for a total transaction of $28,900.00. Following the acquisition, the chief financial officer now owns 10,000 shares of the company's stock, valued at $28,900. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Achieve Life Sciences Trading Up 2.2 %

Shares of ACHV stock traded up $0.06 during mid-day trading on Friday, hitting $2.81. The company's stock had a trading volume of 207,633 shares, compared to its average volume of 170,817. The company has a market cap of $97.46 million, a PE ratio of -2.49 and a beta of 1.67. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.78 and a current ratio of 6.78. The company's fifty day simple moving average is $3.09 and its 200-day simple moving average is $3.95. Achieve Life Sciences, Inc. has a 52 week low of $2.51 and a 52 week high of $5.59.

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last issued its earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.06). As a group, equities research analysts expect that Achieve Life Sciences, Inc. will post -1.17 earnings per share for the current fiscal year.

Remove Ads

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. MetLife Investment Management LLC grew its holdings in Achieve Life Sciences by 65.6% in the third quarter. MetLife Investment Management LLC now owns 14,993 shares of the biopharmaceutical company's stock worth $71,000 after purchasing an additional 5,939 shares during the period. Verition Fund Management LLC acquired a new stake in shares of Achieve Life Sciences in the 3rd quarter valued at about $113,000. State Street Corp grew its stake in shares of Achieve Life Sciences by 6.8% in the 3rd quarter. State Street Corp now owns 431,520 shares of the biopharmaceutical company's stock valued at $2,045,000 after buying an additional 27,419 shares during the period. Barclays PLC increased its position in Achieve Life Sciences by 303.1% in the 3rd quarter. Barclays PLC now owns 47,655 shares of the biopharmaceutical company's stock valued at $226,000 after buying an additional 35,832 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Achieve Life Sciences by 6.9% during the 3rd quarter. Geode Capital Management LLC now owns 749,109 shares of the biopharmaceutical company's stock worth $3,552,000 after buying an additional 48,474 shares during the period. Institutional investors and hedge funds own 33.52% of the company's stock.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.